Breakthrough DNA Repair Inhibitor Advances Rapidly Toward Clinic: Artios’ ART6043 Earns FDA Fast Track Status for Resistant Breast Cancer
Artios Pharma has achieved a significant milestone in cancer treatment development with the U.S. Food and Drug Administration's granting of Fast Track designation to ART6043, a potentially first-in-class DNA polymerase…
Continue Reading
Breakthrough DNA Repair Inhibitor Advances Rapidly Toward Clinic: Artios’ ART6043 Earns FDA Fast Track Status for Resistant Breast Cancer
